Programme

14 CPD points are allocated to the conference in accordance with the CPD scheme of the Royal College of Radiologists.

Day 1
27 Jan 2020
Day 2
28 Jan 2020

Opening

Professor Mitch Dowsett & Baroness Delyth Morgan

Baroness Delyth Morgan
Baroness Delyth Morgan
Professor Mitch Dowsett
Professor Mitch Dowsett

Highlights of the last year

BASIC RESEARCH
Ingunn Holen

TRANSLATIONAL RESEARCH
Nicholas Turner

PRIMARY DISEASE
Andrew Wardley

ADVANCED DISEASE
David Miles

CHAIRS: Julia Gee and Andrew Tutt

Professor Nicholas Turner
Professor Andrew Wardley
Professor Ingunn Holen
Professor Ingunn Holen

Demystifying partial breast irradiation

WHY AND HOW TO DO IT?
Anna Kirby

DOES IT WORK AND WHO SHOULD HAVE IT?
Charlotte Coles

IS LESS REALLY LESS?
Philip Poortmans

CHAIRS: Charlotte Coles & Philip Poortmans

Dr Philip Poortmans
Dr Philip Poortmans
Dr Anna Kirby
Professor Charlotte Coles
Professor Charlotte Coles

Big data in breast cancer

INTRODUCTION: THE CURRENT UK LANDSCAPE
David Dodwell

INVASIVE BREAST CANCER AFTER SCREEN-DETECTED DCIS IN ENGLAND
Gurdeep Mannu

TWENTY FIVE YEAR RISKS OF BREAST CANCER MORTALITY IN 500,000 WOMEN
Carolyn Taylor

ENDOCRINE THERAPY IN THE PRIMARY CARE PRESCRIPTION DATASET
Kieran Horgan

CHAIRS: David Dodwell & Sophia Turner

Mr Kieran Horgan
Dr Gurdeep Mannu
Dr David Dodwell
Dr Carolyn Taylor

Why can’t we kill ER+ breast cancer?

RESISTANCE MECHANISMS TO ENDOCRINE THERAPY
Andy Sims

RESISTANCE MECHANISMS TO CDK4/6 INHIBITION
Ben O’Leary

NEW PROSPECTS FOR KILLING ER+ BREAST CANCER CELLS
Matthew Ellis

CHAIR: Jason Carroll & Stephen Johnston

Dr Matthew Ellis
Dr Matthew Ellis
Dr Andy Sims
Dr Ben O’Leary

Managing the side-effects of endocrine therapy

MANAGING THE SEXUAL IMPACT OF ENDOCRINE THERAPY
Isabel White

HOT FLUSHES
Debbie Fenlon

IMPACT ON TREATMENT ADHERENCE
Mike Dixon

 

CHAIRS: Adrienne Morgan & Anne Armstrong

Dr Isabel White
Professor Mike Dixon
Professor Deborah Fenlon
Professor Deborah Fenlon

SATELLITE SYMPOSIA: EXACT SCIENCES

Prognosis is not enough when making treatment decisions for patients with early breast cancer

Chaired by
Dr Eric Winer, Director of the Breast Oncology Center, Dana-Farber Cancer Institute, Boston

Speakers
Dr Mark Harries, Consultant Medical Oncologist, Guy’s & St Thomas’ NHS FT
Dr Mark Verrill, Consultant Medical Oncologist, The Newcastle Upon Tyne Hospitals NHS FT
Mr Simon Holt, Consultant Surgical Oncologist, Peony Breast Care Unit, Llanelli

Professor Eric Winer

SATELLITE SYMPOSIA: ROCHE

Immune Checkpoint Inhibition in Metastatic Triple Negative Breast Cancer

Chair: Professor Peter Schmid

Speakers:
Prof. Javier Cortés
& Dr Melissa Phillips

SATELLITE SYMPOSIA: PFIZER

Improve outcomes for HR+/HER2- breast cancer patients: a multidisciplinary case-based discussion

Welcome and Introduction:  Dr Alistair Ring, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust

A patient with locally advanced breast cancer: what is the role of Ibrance®q(palbociclib)?
Mr. Henry Cain, Oncoplastic Breast Surgeon, The Newcastle upon Tyne Hospitals NHS Foundation Trust

A patient with metastatic breast cancer, who progressed on adjuvant endocrine treatment: where Ibrance®q(palbociclib) is now an option
Professor Christopher Poole, Consultant Medical Oncologist, University Hospitals Coventry and Warwickshire NHS Trust

A patient with high burden metastatic breast cancer including visceral metastasis: what factors influence the choice of treatment?
Dr. Alistair Ring & Ms. Claire Ryan, Macmillan Nurse Consultant Metastatic Breast Cancer, Maidstone and Tunbridge Wells NHS Trust

Panel discussion

Keynote Lecture: Matthew Ellis

TREATMENT-DEPENDENT BREAST TUMOUR EVOLUTION
Matthew Ellis

CHAIR: Sarah Pinder

Dr Matthew Ellis
Dr Matthew Ellis

Phenotypic and genotypic heterogeneity

GENOMICS OF INVASIVE LOBULAR BREAST CANCER
Christine Desmedt

GENOMIC LANDSCAPE OF BREAST CANCER METASTASIS AND RELAPSE
Adrian Lee

MOLECULAR EVOLUTION OF LYMPH-NODE SPREAD IN EARLY BREAST CANCER – A SURGEON’S INTEREST
Peter Barry

 

CHAIRS: Adrian Lee & Julia Gee

Mr Peter Barry
Dr Adrian Lee
Professor Christine Desmedt

DCIS – Risk estimates and management

MOLECULAR FEATURES OF DCIS AND INVASIVE BREAST CANCER
Elinor Sawyer
ADDRESSING OVERTREATMENT OF SCREEN DETECTED DCIS; THE LORIS TRIAL
Matthew Wallis
NEERA PATEL LECTURE: BREAST CANCER-RELATED DEATHS IN DCIS: THE DUTCH EXPERIENCE
Jelle Wesseling

CHAIRS: Sarah Pinder & Lynda Wyld

Professor Elinor Sawyer
Professor Jelle Wesseling
Dr Matthew G Wallis

Free Communications 1

Chairs: Mark Sibbering & Lesley Turner

1)
10-year results of the International Breast cancer Intervention Study II (IBIS-II)
Jack Cuzick et al

2)
Ethnicity and the surgical management of early invasive breast cancer in over 137 000 women in England
Toral Gathani et al

3)
Surgical outcomes following neoadjuvant chemotherapy – a UK national prospective multi-centre cohort study Stuart A McIntosh et al

4)
Retesting of receptors status (ER, PR and HER2) and proliferation biomarkers (Ki67 and SPAG5) after receiving neoadjuvant chemotherapy (NACT) should be mandatory to guides the choice of the optimal adjuvant therapy in Breast Cancer (BC)
Tarek MA Abdel-Fatah et al

5)
Metabolic reprogramming of ER+ breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib Nicla Lorito et al

Managing the axilla

CAN WE COMPLETELEY AVOID AXILLARY SURGERY FOR SOME BREAST CANCER PATIENTS?
Monica Morrow

UK GUIDELINES FOR MANAGEMENT OF THE AXILLA POST-NACT
Julie Doughty

MODERN ROLE OF THE RADIOLOGIST IN MANAGING THE AXILLA
Anthony Maxwell

 

CHAIRS: Andreas Makris & Mark Sibbering

Dr Monica Morrow
Dr. Tony Maxwell
Dr Anthony Maxwell
Miss Julie Doughty

Late recurrence in ER+ disease

LATE RECURRING ER+ GENOMIC SUBGROUPS
Carlos Caldas

Predicting late recurrence, patient, tissue and circulating factors
Nicholas Turner

PREVENTING LATE RECURRENCE
Ian Smith

CHAIRS: Adrian Lee & Mark Harries

Professor Nicholas Turner
Professor Carlos Caldas
Professor Ian Smith
Professor Ian Smith

Novel clinical trial design

BREAST CANCER TRIALS: CREATING DESIGNS FIT FOR CONTEMPORARY QUESTIONS
Judith Bliss

CAN BAYESIAN ADAPTIVE TRIALS BE USEFUL IN BREAST CANCER?
James Wason

PRESURGICAL WINDOW STUDIES OF NOVEL DRUGS – WHAT’S THE END-POINT?
Adrian Harris

CHAIRS: Judith Bliss & Alistair Ring

Professor Adrian Harris
Professor James Wason
Judith Bliss
Professor Judith Bliss

Keynote Lecture: Eric Winer

CRIDLAN LECTURE
DE-ESCALATION OF MEDICAL ADJUVANT THERAPY

CHAIR: Gill Ross

Professor Eric Winer
18:15-19:15

Drinks reception and poster judging (Session 1)

Keynote Lecture: Martine Piccart

SUCCESSES, DISAPPOINTMENTS AND THE FUTURE FOR CLINICAL TRIALS IN PRIMARY BREAST CANCER

CHAIR: Judith Bliss

Dr Martine Piccart

Modernising breast MDT meetings

IMPROVING MDTM EFFICIENCY – THE DEVELOPMENT OF A MULTIDISCIPLINARY TOOLKIT
Mark Sibbering

MULTIDISCIPLINARY PANEL DISCUSSION
Charlotte Coles; Katy Hogben; Sue Holcombe; Sarah Pinder; Sarah Vinnicombe; Andrew Wardley

INTERACTIVE MDT CASE DISCUSSIONS
Nicola Roche

CHAIRS: Mark Sibbering and Debbie Fenlon

Katy Hogben
Mrs Sue Holcombe
Miss Nicola Roche
Mr Mark Sibbering
Professor Andrew Wardley
Professor Charlotte Coles
Professor Charlotte Coles
Professor Sarah Pinder
Professor Sarah Pinder
Dr. Sarah Vinniecombe
Dr Sarah Vinnicombe

Immune therapy

TREATMENT RESPONSE AND TOXICITIES IN BREAST CANCER
Mark Harries

COMBINED ANALYSIS OF PDL1 AND TILs IN BREAST CANCER: THE NEW NARRATIVE IN DAILY PRACTICE?
Roberto Salgado

CHARACTERISING IMMUNE RESPONSE
Raza Ali

CHAIRS: Andrew Tutt & Adrienne Morgan

Dr Raza Ali
Dr Roberto Salgado
Dr Mark Harries

Modelling breast cancer – moving closer to the clinic

HORMONES AND BREAST CANCER – WHY MODELS MATTER
Cathrin Brisken

A NEW 3D MODEL FOR BREAST CANCER – ALTERNATIVES TO XENOGRAFTS AND PDX
Gillian Farnie

THE CHALLENGES OF MEASURING THE RESPONSE TO IMMUNOTHERAPIES IN VIVO
Jonas Nillson

CHAIRS: Ingunn Holen & Rob Clarke

Professor Cathrin Brisken
Professor Jonas Nillson

Trials in progress

Multidisciplinary aspects of clinical trials

SMALL: DR Nisha Sharma

POSNOC and ATNEC: Dr Duncan Wheatley

PRIMETIME: Cliona Kirwan

OPTIMA: Dr Andreas Makris

POETIC -A: Dr Alistair Ring

CHAIRS: Dan Rea & Carlo Palmieri

Dr Alistair Ring
Professor Cliona Kirwan
Dr. Andreas Makris
Dr Andreas Makris

Keynote Lecture: Judy Garber

GENETICS AND BREAST CANCER RISK

CHAIR: Trevor Powles

Dr Judy Garber

Breast Cancer Risk and Prevention

RECENT LESSIONS FROM THE WHI STUDY
Rowan Chlebowski

CHEMOPREVENTION OF BREAST CANCER – WHERE HAVE WE GOT TO?
Jack Cuzick

LOW-DOSE TAMOXIFEN FOR BREAST CANCER PREVENTION
Andrea De Censi

 

CHAIRS: Trevor Powles & Anne Armstrong

Dr Andrea De Censi

Prognostic and Predictive Profiling

PREDICT VS NPI
Paul Pharoah

CAN MRNA REPLACE IHC FOR ER?
Adrian Lee

KI67 – WILL IT EVER MAKE IT? A REPORT OF 10 YEARS’ WORK FROM THE INTERNATIONAL KI67 IN BREAST CANCER WORKING GROUP
Mitch Dowsett

CHAIRS: Kieran Horgan & Steffi Oesterreich

Professor Paul Pharoah
Dr Adrian Lee
Professor Mitch Dowsett
Professor Mitch Dowsett

Special issues in managing young patients

CHOOSING ENDOCRINE TREATMENT
Daniel Rea

MANAGING FERTILITY IN BREAST CANCER
Melanie Davies

PREGNANCY AFTER BREAST CANCER
Sibylle Loibl

 

CHAIRS: Andrew Wardley & Liz O’Riordan

Dr Melanie Davies
Professor Sibylle Loibl
Professor Daniel Rea

Free Communications: 2

Chairs: Andy Sims & David Miles

1)
Pathological features and outcome of screen detected ductal carcinoma in situ (DCIS):  Updated analysis from the UK Sloane Project
Abeer M Shaaban et al

2)
Fulvestrant plus capivasertib versus placebo in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial
Sacha Jon Howell et al

3)
Results from plasmaMATCH: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer
Alistair Ring et al

4)
Whole-genome-sequencing of triple negative breast cancers in a standard population-based clinical setting Johan Staaf et al

5)
A 3D-printed electrochemical sensor for measuring reactive oxygen/nitrogen species production from breast cancer cells and ex vivo-cultured tumour tissue
William E Jones et al

SATELLITE SYMPOSIA: LILLY

Chair:
• Dr Marina Parton, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust
Panel:
• Professor David Cameron, Professor of Medical Oncology, Cancer Research UK Edinburgh Centre
• Suzanne Frank, Advanced Specialist Breast Cancer Pharmacist, The Christie NHS Foundation Trust
• Dr Judy King, Consultant Medical Oncologist, Royal Free London NHS Foundation Trust
• Maria Noblet, Consultant Nurse in Breast Cancer, Portsmouth Hospitals NHS Trust
• Dr Duncan Wheatley, Clinical Oncologist, Royal Cornwall Hospitals NHS Trust

Welcome and introduction
Overview of the mBC treatment landscape and emergence of CDK4/6 inhibitors Dr Marina Parton (Chair)
A case in point: benefit in bone metastases*
Case presentation, audience voting and panel discussion Dr Judy King
Panel discussion
A case in point: leveraging CDK4 & 6 inhibitors in liver lesions*
Case presentation, audience voting and panel discussion Professor David Cameron
Panel discussion
A case in point: defying primary endocrine resistance*
Case presentation, audience voting and panel discussion
Abemaciclib overall survival data presentation Dr Duncan Wheatley
Panel discussion
Summary and close Dr Marina Parton (Chair)
*Educational topics including scheduling treatments and managing toxicities discussed within the case studies.

SATELLITE SYMPOSIA: DAIICHI SANKYO

Challenges in Biomarker interpretation in the real world – An MDT discussion

Panellists:
Professor Dan Rea (chair)
Dr Rebecca Roylance
Mr Stuart McIntosh
Dr Abeer Shaaban
Professor Christopher Poole

SATELLITE SYMPOSIA: NANOSTRING

Identifying Breast Cancer Biomarkers for Understanding Heterogeneity of Response

Speaker: Rudy van Eijsden, Senior Product Application Scientist NanoString
Using the NanoString nCounter® and GeoMx™ DSP platforms to advance breast cancer research.

Speaker: Dr Sheeba Irshad CRUK Clinician Scientist & Honorary Medical Oncologist Guy’s Hospital King’s College London, UK
Investigating the immune landscape of chemotherapy resistant early breast cancers

Keynote Lecture: Monica Morrow

DE-ESCALATING SURGERY FOR BREAST CANCER

CHAIR: Julie Doughty

Dr Monica Morrow

Special issues for elderly patients

SPECIAL ISSUES ON OLDER PATIENTS WITH PRIMARY BREAST CANCER
KL Cheung

BRIDGING THE AGE GAP
Lynda Wyld

DEMENTIA AND DECISION MAKING
Yasmin Jauhari

CHAIRS: KL Cheung & Alistair Ring

Dr Yasmin Jauhari
Professor Kwok-Leung Cheung
Professor Lynda Wyld

Minimising mastectomy

NEOADJUVANT CHEMOTHERAPY
Sibylle Loibl

BREAST CONSERVING SURGERY FOR MULTIFOCAL TUMOURS
Mike Dixon

ONCOPLASTIC SURGERY
Katy Hogben

CHAIRS: Julie Doughty & Andreas Makris

Katy Hogben
Professor Sibylle Loibl
Professor Mike Dixon

Translating new therapeutic opportunities

TARGETING CDK7 IN ER+ BREAST CANCER
Simak Ali

ANDROGEN RECEPTOR AGONISTS FOR AR+ DISEASE
Carlo Palmieri

PROSPECTS FOR TARGETING FOXA1
Jason Carroll

CHAIRS: Rob Clarke & Adrian Harris

Professor Carlo Palmieri
Professor Simak Ali
Professor Jason Carroll

Young Clinical Leaders

TRAINEE COLLABORATIVE RESEARCH – A SUCCESSFUL NEW STORY
Cliona Kirwan

THE ACHIEVEMENTS OF THE MAMMARY FOLD COLLABORATIVE AND CURRENT PROJECTS
Lisa Sheehan

MULTIDISCIPLINARY COLLABORATION – INTRODUCTION TO THE BCTRCG
Ellen Copson

DRAGON’S DEN
Tim Robinson
Sheeba Irshad
Teo Pei Jing

ACADEMIC CAREER PATHWAYS
Cliona Kirwan

WHY AND HOW TO JOIN A TRIAL MANAGEMENT GROUP
Indrani Bhattacharya

Chairs: Cliona Kirwan and Ellen Copson

Dr Pei Jing Teo
Professor Cliona Kirwan
Dr Ellen Copson
Dr Lisa Sheehan
Dr Indrani Bhattacharya